Recursion Pharmaceuticals, Inc. beat EPS estimates 100% of the time across 1 reported quarters (1 beats, 0 misses). Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|
| Q22026 FY2026 | $-0.25 | — | — | Miss |
| Q12026 FY2026 | $-0.30 | $-0.22 | +26.7% | Beat |
| 2026-02-27 | $-0.28 | — | — | Miss |
Back to RXRX overview · RXRX holders · RXRX KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.